Eliminating the need for fasting with oral administration of bisphosphonates

Figures & data

Figure 1 Bisphosphonate structure, bone mineral binding, and biochemical mechanisms.

Note: Reproduced from Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bispho sphonate therapy. J Bone Miner Res. 2010;25:2–10.⁴ With permission of the American Society for Bone and Mineral Research.

Figure 2 Inhibition of the mevalonate pathway by statins and bisphosphonates.

Note: Reproduced from Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bispho sphonate therapy. J Bone Miner Res. 2010;25:2–10.⁴ With permission of the American Society for Bone and Mineral Research.
Abbreviation: HMG Co-A, 3-hydroxy-3-methylglutarylcoenzyme A.

Figure 3 Paracellular, transcellular route, and tight junctions.

Figure 4 Fasting has been identified as one of the three main reasons for discontinuing treatment.

Note: Reproduced with permission from International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don’t continue with treatment.²⁰

Figure 5 Mean percent change from baseline ± standard error of the mean in (A) bone mineral density and (B) bone turnover markers over 2 years in women receiving risedronate 5 mg immediate-release daily (solid lines with black circles), 35 mg delayed-release immediately following breakfast weekly (dashed lines with black squares), or 35 mg delayed-release at least 30 minutes before breakfast weekly (circle dashed lines with black triangles). Asterisk represents statistically significant difference between immediate-release daily and delayed-release weekly treatment group.

Note: With kind permission from Springer Science+Business Media: McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR. Treatment of postmenopausal osteoporosis with delayed-release rise dronate 35 mg weekly for 2 years. Osteoporos Int. 2013;24:301–310.²⁹
Abbreviations: CTX, C-terminal telopeptide; SE, standard error of the mean; CR, creatinine; BAP, bone alkaline phosphatase.

PazianasMCompstonJHuangCL-HAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res20102521020091928

 PubMed Web of Science ®Google Scholar

International Osteoporosis FoundationThe adherence gap: why osteoporosis patients don’t continue with treatment Available from: http://www.iofbonehealth.org/sites/default/files/PDFs/adherence_gap_report_2005.pdfAccessed September 12, 2013

 Google Scholar

McClungMRBalskeABurgioDEWenderothDReckerRRTreatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsOsteoporos Int20132430131023079690

 PubMed Web of Science ®Google Scholar